Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 6, 2026

Arrowhead receives Health Canada authorisation for Redemplo to treat FCS

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, Redemplo (plozasiran), as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) who have not responded to standard therapies.

Continue
The therapy can be self-administered at home via subcutaneous injection every three months. Credit: Davidzro Photography / Shutterstock.com.
January 6, 2026

Takeda and Protagonist seek FDA approval for rusfertide to treat PV

The application includes findings from the Phase II REVIVE study. Credit: Minerva Studio / Shutterstock.com.
January 5, 2026

Insilico and Servier announce $888m oncology research agreement

Insilico has developed an oncology pipeline targeting several cancer indications. Credit: metamorworks / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Samsung Bioepis initiates Byooviz commercialisation in Europe
  2. Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
  3. Samsung Biologics to acquire Human Genome Sciences
  4. Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
  5. MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography